STAA

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

STAAR Surgical Co revenue for the last quarter amounts to 94.73M USD, increased 6.93 % YoY.

STAAR Surgical Co. EPS for the last quarter amounts to 0.18 USD, decreased -10.00 % YoY.

STAAR Surgical Co (STAA) has 1157 emplpoyees as of December 15 2025.

Today STAA has the market capitalization of 1.20B USD.